Triastek has successfully treated ulcerative colitis by directly targeting the colon with their latest 3D printed drug.

Share this story

3D Printing in Pharmaceuticals: A Revolutionary Breakthrough in Healthcare

In recent years, 3D printing has transformed various industries, and now it is making its way into healthcare, particularly in the field of pharmaceuticals. This technology has the potential to create custom drugs for better treatment of diseases, and several companies are exploring its use in this area. Among them, Chinese manufacturer Triastek has announced a significant success in a groundbreaking study.

Triastek recently conducted a first in human (FIH) study for its third 3D printed drug product, called T21. The study successfully demonstrated the drug’s ability to target the colon for the treatment of moderate to severe ulcerative colitis (UC). This is a remarkable achievement, as it is the first time a colon targeting platform has been verified in human trials.

Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the large intestine, known as the colon. While there is no cure for this condition, timely and effective treatment is crucial to prevent life-threatening complications such as a perforated colon, increased risk of blood clots, severe bleeding, and dehydration.

According to statistics from the Mayo Clinic, ulcerative colitis affects a significant number of individuals in the United States, with an estimated 156 to 291 cases per 100,000 persons each year. This means that approximately 600,000 to 900,000 people in the U.S. are currently living with this disease.

Traditionally, oral medication has been the preferred method of drug administration for gastrointestinal diseases. However, its effectiveness can vary greatly among patients due to differences in the digestive environment and mucosal transport mechanisms across the gastrointestinal tract. As a result, drug delivery to specific locations within the gastrointestinal system has been challenging.

This is where Triastek’s 3D printed drug, T21, comes into play. Developed using the company’s self-developed process called the 3D Microstructure for Colon Targeting (3DµS-CT), T21 is an oral colon-targeted delivery drug that has already received FDA approval. The 3DµS-CT process allows Triastek to create a 3D printed prototype with various combinations of multiple release control mechanisms, enabling them to achieve precise drug delivery to the colon.

The technique builds upon Triastek’s Melt Extrusion Deposition (MED) proprietary 3D technology, which has also been used in the creation of other 3D printed drugs by the company. With a specially-built 3D printer, powdered raw materials are mixed and fused into a movable semi-solid, which is then extruded and printed layer by layer to form three-dimensional drug tablets.

The FIH-tested T21 tablet consists of three layers: an enteric layer, a delay layer, and a drug core. The enteric layer maintains the tablet’s overall structure in the acidic environment of the stomach and is pH-dependent. As the tablet moves into the small intestine, the enteric layer rapidly erodes to expose the delay layer. The delay layer, which is time-dependent, continues to erode at a constant rate in the intestinal tract. The erosion rate of this layer can be adjusted to suit each patient by varying the thickness of the pre-selected polymer material. Finally, when the tablet reaches the ascending colon, it fully erodes, revealing the drug core containing the active ingredients, which have now reached their targeted area for maximum impact.

The success of the FIH study confirms the ability of T21 to precisely target the colon, offering new hope for the treatment of gastrointestinal diseases. Professor Xiaoling Li, co-founder and chief scientific officer of Triastek, expressed his excitement about the study’s results, stating, “The first in human study data with T21 verifies the precise colon delivery capability of the MED process.”

This breakthrough in 3D printed drug technology marks another milestone in the healthcare industry’s continuous efforts to provide personalized and effective treatments. As 3D printing technology continues to advance, we can expect further innovations that will revolutionize healthcare and improve patient outcomes.

Are you tired of traditional drug delivery systems that don’t effectively target specific areas of the body? Well, Triastek may have the solution for you – their revolutionary 3D printing processes.

Triastek’s platform is poised to become the go-to method for delivering new drugs to the colon. Whether it’s a product that needs to have a local effect or one that requires systemic absorption, Triastek’s technology aims to provide pharmaceutical companies with an efficient and optimized way to develop these drug delivery systems.

But what exactly does this mean for patients? Well, it means that they could soon have access to more clinically valuable medicines. By using Triastek’s 3D printing processes, pharmaceutical companies can create drugs that are specifically tailored to target certain areas of the colon. This precision targeting can lead to improved treatment outcomes and better overall patient care.

So, how does Triastek’s technology work? It starts with their advanced 3D printing processes, which allow for the creation of highly complex drug delivery systems. These systems can be designed to release the drug in a controlled manner, ensuring that it reaches its intended target in the colon. This level of precision is unprecedented in traditional drug delivery methods.

Triastek’s commitment to innovation is evident in their partnerships with pharmaceutical companies. They strive to bring technical solutions to these companies, helping them streamline their product development processes. By using Triastek’s technology, pharmaceutical companies can accelerate the time it takes to bring new drugs to market, ultimately benefiting patients who are in need of these medications.

If you want to learn more about Triastek’s groundbreaking technology, be sure to check out their press release, which can be found on their website. And don’t forget to follow their social media pages for the latest updates on their advancements in drug delivery.

In conclusion, Triastek’s 3D printing processes have the potential to revolutionize drug delivery. Their platform offers pharmaceutical companies an efficient and optimized way to develop targeted drug delivery systems for the colon. This level of precision can lead to more clinically valuable medicines for patients. So, keep an eye out for Triastek’s future innovations in the field of drug delivery – they could be the key to improving patient care and treatment outcomes.

Original source

Share this story

Leave a Reply

Your email address will not be published. Required fields are marked *